Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Heartland Bank & Trust Co

Heartland Bank & Trust Co decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 578 shares of the biopharmaceutical company’s stock after selling 30 shares during the period. Heartland Bank & Trust Co’s holdings in Regeneron Pharmaceuticals were worth $412,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $26,000. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter worth $37,000. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $39,000. Finally, Valley Wealth Managers Inc. purchased a new stake in Regeneron Pharmaceuticals during the third quarter worth about $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several analyst reports. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Citigroup reduced their target price on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating on the stock in a report on Tuesday, January 14th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Finally, Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Trading Down 2.7 %

Shares of Regeneron Pharmaceuticals stock opened at $675.79 on Monday. The company has a 50-day moving average of $727.19 and a two-hundred day moving average of $936.01. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market cap of $74.26 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.